

Nithya Ramnath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10552494/publications.pdf>

Version: 2024-02-01

76
papers

5,985
citations

101543

36
h-index

76900

74
g-index

77
all docs

77
docs citations

77
times ranked

10576
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer. <i>Lung Cancer</i> , 2022, 163, 35-41.	2.0	15
2	Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 614.	3.7	23
3	Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.8	10
4	Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 1170-1176.	8.6	33
5	Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 752-758.	0.8	5
6	Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	1
7	Molecular biomarkers and liquid biopsies in lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 275-284.	2.2	2
8	Onâ€Chip Biogenesis of Circulating NK Cellâ€Derived Exosomes in Nonâ€Small Cell Lung Cancer Exhibits Antitumoral Activity. <i>Advanced Science</i> , 2021, 8, 2003747.	11.2	50
9	Characterization of pneumonia and other factors leading to poorer survival across all age groups in patients with non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Disease</i> , 2021, 13, 986-994.	1.4	0
10	Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e210980.	5.9	16
11	Isolation of Circulating Biomarkers for Liquid Biopsy using Immunoaffinityâ€Based Stimuliâ€Responsive Hybrid Hydrogel Beads. <i>Analysis & Sensing</i> , 2021, 1, 117-129.	2.0	3
12	Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Nonâ€Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 915-921.	4.9	27
13	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. <i>Nature Medicine</i> , 2021, 27, 152-164.	30.7	451
14	The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients?. <i>Cancers</i> , 2021, 13, 13.	3.7	21
15	Epidermal Growth Factor Receptor Mutations Carried in Extracellular Vesicle-Derived Cargo Mirror Disease Status in Metastatic Non-small Cell Lung Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 724389.	3.7	0
16	High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 127.	3.7	60
17	A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 170-177.	0.8	13
18	Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC. <i>Advanced Biology</i> , 2020, 4, e2000110.	3.0	12

#	ARTICLE	IF	CITATIONS
19	The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independent of its catalytic activity. <i>Journal of Biological Chemistry</i> , 2020, 295, 5906-5917.	3.4	7
20	Reactive Oxygen Species in the Tumor Microenvironment: An Overview. <i>Cancers</i> , 2019, 11, 1191.	3.7	288
21	Isolation and Profiling of Circulating Tumor-Associated Exosomes Using Extracellular Vesicular Lipid-Protein Binding Affinity Based Microfluidic Device. <i>Small</i> , 2019, 15, e1903600.	10.0	106
22	PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer. <i>Scientific Reports</i> , 2019, 9, 566.	3.3	90
23	Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. <i>Cancer Research</i> , 2019, 79, 3940-3951.	0.9	154
24	Validation of a serum 4-microRNA signature for the detection of lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 636-648.	2.8	15
25	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 559-564.	2.6	12
26	Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship. <i>Radiotherapy and Oncology</i> , 2017, 125, 66-72.	0.6	14
27	Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. <i>Cancer Research</i> , 2017, 77, 5194-5206.	0.9	139
28	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017, 548, 297-303.	27.8	685
29	Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 269-280.	1.1	23
30	Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, 397-402.	1.1	37
31	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.	1.8	45
32	Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection. <i>Cancers</i> , 2016, 8, 61.	3.7	12
33	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. <i>Cancer Medicine</i> , 2016, 5, 2567-2578.	2.8	56
34	Pulmonary venous blood sampling significantly increases the yield of circulating tumor cells in early-stage lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 852-858.	0.8	53
35	The "liquid biopsy" in non-small cell lung cancer "not quite ready for prime time use. <i>Translational Cancer Research</i> , 2016, 5, S632-S635.	1.0	3
36	KRAS-G12C Mutation is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e9-e10.	1.1	16

#	ARTICLE	IF	CITATIONS
37	A Novel Serum 4-microRNA Signature for Lung Cancer Detection. <i>Scientific Reports</i> , 2015, 5, 12464.	3.3	111
38	MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer. <i>Scientific Reports</i> , 2015, 5, 11471.	3.3	19
39	Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions. <i>Frontiers in Oncology</i> , 2015, 5, 209.	2.8	48
40	Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2015, 6, 156.	2.3	8
41	Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. <i>Oncotarget</i> , 2014, 5, 12383-12397.	1.8	175
42	Epigenetic Regulation of Vitamin D Metabolism in Human Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 473-482.	1.1	28
43	Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 222-230.	1.1	14
44	Effects of Cigarette Smoking on Metabolism and Effectiveness of Systemic Therapy for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 917-926.	1.1	99
45	KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1513-1522.	1.1	108
46	A MicroRNA Cluster at 14q32 Drives Aggressive Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 3107-3117.	7.0	92
47	A Radial Flow Microfluidic Device for Ultra-High-Throughput Affinity-Based Isolation of Circulating Tumor Cells. <i>Small</i> , 2014, 10, 4895-4904.	10.0	115
48	Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. <i>Nature Nanotechnology</i> , 2013, 8, 735-741.	31.5	487
49	Cigarette Smoking and Gemcitabine-Induced Neutropenia in Advanced Solid Tumors. <i>Oncology</i> , 2013, 85, 216-222.	1.9	17
50	Treatment of Stage III Non-small Cell Lung Cancer. <i>Chest</i> , 2013, 143, e314S-e340S.	0.8	381
51	Changes in Global Function and Regional Ventilation and Perfusion on SPECT During the Course of Radiotherapy in Patients With Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e631-e638.	0.8	46
52	Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. <i>Lung Cancer</i> , 2012, 77, 265-271.	2.0	58
53	Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1117-1120.	1.1	29
54	Semiquantification and Classification of Local Pulmonary Function by V/Q Single Photon Emission Computed Tomography in Patients with Non-small Cell Lung Cancer: Potential Indication for Radiotherapy Planning. <i>Journal of Thoracic Oncology</i> , 2011, 6, 71-78.	1.1	37

#	ARTICLE	IF	CITATIONS
55	Development and Validation of a Quantitative Real-Time Polymerase Chain Reaction Classifier for Lung Cancer Prognosis. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1481-1487.	1.1	30
56	Vitamin D and lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 305-309.	2.5	12
57	CYP24A1 Is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 817-826.	7.0	96
58	Phase II Trial of Imatinib Maintenance Therapy After Irinotecan and Cisplatin in Patients With c-KIT Positive, Extensive-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 223-227.	2.6	48
59	Apoptosis-Related (Survivin, Bcl-2), Tumor Suppressor Gene (p53), Proliferation (Ki-67), and Non-Receptor Tyrosine Kinase (Src) Markers Expression and Correlation With Clinicopathologic Variables in 60 Thymic Neoplasms. <i>Chest</i> , 2009, 136, 220-228.	0.8	26
60	Progress in the Treatment of Metastatic Non-Small-Cell Lung Cancer: Slow but Steady!. <i>Clinical Lung Cancer</i> , 2009, 10, 260-261.	2.6	0
61	Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1117-1125.	1.1	40
62	In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 881-891.	2.3	39
63	Up-Regulation of Peroxiredoxin 1 in Lung Cancer and Its Implication as a Prognostic and Therapeutic Target. <i>Clinical Cancer Research</i> , 2008, 14, 2326-2333.	7.0	82
64	Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. <i>Anti-Cancer Drugs</i> , 2008, 19, 749-752.	1.4	4
65	Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , 2007, 25, 1698-1704.	1.6	437
66	Elevated Peroxiredoxin 1, but not NF-E2-Related Factor 2, Is an Independent Prognostic Factor for Disease Recurrence and Reduced Survival in Stage I Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3875-3882.	7.0	73
67	Pneumonectomy for Bronchogenic Carcinoma: Analysis of Factors Predicting Survival. <i>Annals of Thoracic Surgery</i> , 2007, 83, 1831-1836.	1.3	27
68	Phase II Study of Neoadjuvant Chemotherapy With Gemcitabine and Vinorelbine in Resectable Non-small Cell Lung Cancer. <i>Chest</i> , 2005, 128, 3467-3474.	0.8	21
69	Nuclear or cytoplasmic expression of survivin: What is the significance?. <i>International Journal of Cancer</i> , 2005, 114, 509-512.	5.1	225
70	Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3218-3229.	1.6	51
71	Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. <i>Modern Pathology</i> , 2004, 17, 430-439.	5.5	67
72	Matrix metalloproteinase inhibitors. <i>Current Oncology Reports</i> , 2004, 6, 96-102.	4.0	100

#	ARTICLE	IF	CITATIONS
73	Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 227-230.	2.3	13
74	Loss of cables protein expression in human non-small cell lung cancer: A tissue microarray study. <i>Human Pathology</i> , 2003, 34, 143-149.	2.0	27
75	HER-2/ neu Protein Expression and Gene Alteration in Stage IIIA Non-Small-Cell Lung Cancer: A Study of 140 Cases Using a Combination of High Throughput Tissue Microarray, Immunohistochemistry, and Fluorescent In Situ Hybridization. <i>Diagnostic Molecular Pathology</i> , 2003, 12, 201-211.	2.1	71
76	MCM2 Is an Independent Predictor of Survival in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 4259-4266.	1.6	123